AIM Immunotech vs Vivosim Labs
Vivosim Labs is the larger business, with $131,000 of revenue in fiscal 2026 against $88,000 for AIM Immunotech (1.5 times as much). Vivosim Labs grew faster (-9.0% against -48.2%). Vivosim Labs kept more of each dollar of sales as profit: a net margin of -10567.2% against -15861.4%.
| Latest fiscal year | AIM ImmunotechAIM, 2025 | Vivosim LabsVIVS, 2026 |
|---|---|---|
| Revenue | $88,000 | $131,000 |
| Revenue growth | -48.2% | -9.0% |
| Net income | −$14.0m | −$13.8m |
| Operating margin | -13254.5% | -8768.7% |
| Net margin | -15861.4% | -10567.2% |
| Return on equity | — | — |
| Free cash flow | −$11.0m | −$10.8m |
| Cash | $3.0m | $5.0m |
| Total debt | $8.0m | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 19 | 15 |
| Market value | $4.7m | $457,742 |
| Price vs our value range | — | — |
| Moat score | 5 (Weak) | 18 (Weak) |
| Insider trades, 12 months | 6 buys, 0 sales | 1 buys, 1 sales |